PREDNISONA TARBIS 5 mg TABLETS

Introduction

Package Leaflet: Information for the Patient

Prednisona Tarbis 5 mg tablets EFG

prednisona

Read this package leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this package leaflet, you may need to read it again.
• If you have any further questions, ask your doctor or pharmacist or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others, as it may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this package leaflet.

Contents of the package leaflet:

1. What is Prednisona Tarbis and what is it used for
2. What you need to know before you start taking Prednisona Tarbis
3. How to take Prednisona Tarbis
4. Possible side effects
5. Storage of Prednisona Tarbis
6. Contents of the pack and further information

1. What is Prednisona Tarbis and what is it used for

Prednisona is a corticosteroid (glucocorticoid) derived from cortisone.

It regulates many of the body's metabolic processes.

Prednisona Tarbis 5 mg tablets are used for the treatment of:

• acute and chronic rheumatic and muscular processes,
• bronchial asthma and pulmonary fibrosis,
• ulcerative colitis (inflammatory bowel disease),
• hepatitis,
• Addison's disease,
• adrenogenital syndrome,
• kidney and urinary tract diseases,
• allergic and inflammatory skin processes,
• hemolytic anemias,
• agranulocytosis (absence of blood defense cells),
• rheumatic purpura,
• acute leukemia and other hematological diseases,
• some inflammatory eye diseases (allergic conjunctivitis, keratitis, chorioretinitis, iritis, iridocyclitis).

2. What you need to know before you start taking Prednisona Tarbis

Do not take Prednisona Tarbis

• If you are allergic to prednisona or any of the other ingredients of Prednisona Tarbis 5 mg tablets.
• In cases of osteomalacia and osteoporosis.
• If you have diabetes mellitus.
• If you suffer from psychosis.
• In case of peptic ulcer.
• In cases of active tuberculosis (unless chemotherapeutic drugs are used simultaneously).
• In acute bacterial infections.
• If you have chickenpox or herpes.
• In cases of systemic fungal infections.
• If you need to be vaccinated, do not take prednisona during the 8 weeks prior to vaccination or 2 weeks after vaccination.
• In cases of severe arterial hypertension.
• If you have glaucoma.

Warnings and precautions

• Tell your doctor if you are taking or have recently taken other medicines, including those obtained without a prescription.
• Some medicines may increase the effects of Prednisona Tarbis, so your doctor will monitor you closely if you are taking these medicines (including some for HIV: ritonavir, cobicistat).
• Contact your doctor if you experience blurred vision and other visual disturbances.

Consult your doctor or pharmacist before starting to take Prednisona Tarbis.

• If you have risk factors for osteoporosis: family history, advanced age, post-menopause, significant smoking, and lack of physical activity, as treatment with prednisona may cause bone mass loss. In these situations, your doctor may prescribe treatment to prevent osteoporosis.
• In prolonged treatments with Prednisona Tarbis, your doctor may prescribe potassium supplements and reduce sodium intake.
• In case of severe heart failure, careful medical monitoring is required.
• In cases of poor thyroid function (hypothyroidism) or liver cirrhosis, lower doses than those recommended may be sufficient.
• After a long treatment period, if you need to stop taking Prednisona Tarbis or interrupt its administration, you may experience a relapse of another disease you suffer from, acute adrenal insufficiency (especially if you have an infection or after an accident), or cortisone withdrawal syndrome.
• Chickenpox or measles can be particularly severe in patients undergoing treatment with glucocorticoids. This should be taken into account especially in children with diminished defenses and in people who have not had measles or chickenpox.
• In cases of prolonged treatment in children, the pancreas may be damaged.
• Taking Prednisona Tarbis may give false results in skin tests for allergy tests.
• If you have scleroderma (also called systemic sclerosis, an autoimmune disorder), because daily doses equal to or greater than 15mg may increase the risk of a serious complication called scleroderma renal crisis. The signs of a scleroderma renal crisis are increased blood pressure and decreased urine production. Your doctor may advise you to periodically check your blood pressure and urine.

Interaction of Prednisona Tarbis with other medicines

Tell your doctor or pharmacist if you are using or have recently used other medicines, including those obtained without a prescription.

• Rifampicin, phenytoin, carbamazepine, and barbiturates may decrease the effect of prednisona. Erythromycin and ketoconazole may increase it.
• Contraceptives containing estrogens may increase the effect of prednisona.
• Antacids (aluminum, magnesium) may decrease the absorption, and therefore the effectiveness of prednisona.
• If you take medicines for the treatment of diabetes, the effects of the latter on blood sugar levels may be lower.
• If you take coumarin derivatives (medicines to control blood coagulation), the anticoagulant effect of the latter may be decreased.
• Taking prednisona with digitalis, diuretics, or amphotericin B may cause changes in potassium levels.
• Taking prednisona with non-steroidal anti-inflammatory drugs or antirheumatics (indomethacin, acetylsalicylic acid) may increase the risk of gastrointestinal bleeding.
• The effects of muscle relaxants may be increased if taken with prednisona.
• Because their activity is mutually inhibited, prednisona should not be given with cyclosporin.
• The administration of prednisona with cyclophosphamide may modify the effects of the latter.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Prednisona Tarbis should not be taken during pregnancy unless your doctor prescribes it.

If symptoms of acute diseases such as infectious, digestive, or mental disorders appear during treatment, consult your doctor.

Prednisona Tarbis should not be taken during breastfeeding unless your doctor prescribes it. He will indicate whether you should stop breastfeeding or interrupt the administration of this medicine.

Driving and using machines

It should be taken into account that in long-term treatments, visual acuity may decrease.

This could negatively affect the ability to drive and use machinery.

Prednisona Tarbis 5 mg tabletscontain lactose.

If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medicine.

Use in athletes

Athletes are informed that this medicine contains a component that may produce a positive result in doping tests.

3. How to take Prednisona Tarbis

Follow the instructions for administration of this medicine exactly as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Remember to take your medicine.

The tablets should be taken whole with sufficient liquid. The total daily dose will be divided into three or four doses, during or after meals. In some cases, the prescribed dose may be taken in a single daily dose, during or after breakfast. Sometimes, especially in children, and only when your doctor has indicated it, the treatment will be taken on alternate days.

Your doctor will decide the dose you should take, adjusting it to your needs.

Prednisona Tarbis 5 mg tablets should not be stopped abruptly, but the dosage will be gradually reduced.

In general, the maintenance dose should always be the lowest possible.

Your doctor will indicate the duration of your treatment with Prednisona Tarbis 5 mg tablets.

Do not stop treatment before or abruptly, as it may worsen your disease.

If you think the effect of Prednisona Tarbis 5 mg tablets is too strong or too weak, tell your doctor.

Adults:

The treatment dose will depend on the type and severity of the disease and the individual patient's response. The initial dose is usually 20 to 60 mg per day, as prescribed by your doctor. These initial doses will be administered until a satisfactory response is observed.

When this occurs, your doctor will gradually reduce the dose of Prednisona Tarbis until the maintenance dose is reached, which is usually between 5 and 10 mg per day. In bronchial asthma, the procedure is the same, although the initial dose in very severe cases is between 15 and 60 mg.

Children:

In general, treatment with prednisona in children can be done on alternate days or intermittently. The recommended initial doses are 1 to 3 mg of prednisona per kilogram of body weight and day.

The maintenance dose is 0.25 mg of prednisona per kilogram of body weight and day.

If you take more Prednisona Tarbis than you should

Acute overdoses with prednisona are not known. In case of overdose, it is expected that the adverse reactions described in this package leaflet will occur to a greater extent. Overdose may cause excitement, anxiety, depression, mental confusion, gastrointestinal bleeding, increased blood pressure, and blood sugar levels, as well as fluid retention (edema).

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.

If you forget to take Prednisona Tarbis

Do not take a double dose to make up for forgotten doses. Wait for the next dose and continue treatment as usual.

If you stop treatment with Prednisona Tarbis

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Prednisona Tarbis can cause side effects, although not everybody gets them.

• In prolonged treatments, some localized obesity may appear in the abdomen and face (moon face), increased blood sugar, loss of bone calcium (osteoporosis), increased blood pressure, appearance of hair, acne, suppression of menstruation, sexual impotence in men, and growth retardation in children.
• Glaucoma, cataracts.
• Excitement, irritability, and increased appetite.
• Muscle atrophy and pain.
• Gastroduodenal ulcer and gastrointestinal bleeding.
• Wounds take longer to heal and skin stretch marks may appear.
• Some infections may go unnoticed and there may be less resistance to them.
• Blood disorders: decrease in the number of white blood cells or increase in the number of red blood cells.
• Frequency not known: Scleroderma renal crisis in patients who already have scleroderma (an autoimmune disorder). The signs of a scleroderma renal crisis are increased blood pressure and decreased urine production.
  • Frequency not known: Decreased heart rate

Blurred vision.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Health Products Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Prednisona Tarbis

Keep this medicine out of the sight and reach of children.

No special storage conditions are required.

Do not use Prednisona Tarbis after the expiration date stated on the packaging after "EXP". The expiration date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the pharmacy's SIGRE collection point. If you are unsure, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and further information

Composition of Prednisona Tarbis 5 mg tablets

The active ingredient is prednisona. Each tablet contains 5 mg of prednisona.

The other ingredients (excipients) are:

Lactose monohydrate, sodium carboxymethyl starch Type A (potato), magnesium stearate, anhydrous colloidal silica, and talc.

Appearance of the product and pack contents

White, cylindrical, biconvex tablets, scored on one side and with the inscription PD5 on the other.

The tablets can be divided into equal parts.

Prednisona Tarbis 5 mg tablets EFGare packaged in PVC-PVDC/Aluminum blisters.

Prednisona Tarbis 5 mg tablets EFGare available in packs containing 30 or 60 tablets.

Marketing authorization holder and manufacturer:

Marketing authorization holder

Tarbis Farma, S.L.

Gran Vía Carlos III, 94

08028 Barcelona - Spain

Manufacturer

Laboratorios Cinfa, S.A.

C/ Olaz-Chipi, 10 - Polígono Industrial Areta.

31620 Huarte - Pamplona (Navarra) - Spain

Date of the last revision of this package leaflet:October 2021

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) www.aemps.gob.es/